--- title: "Immuneering | 8-K: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286558957.md" datetime: "2026-05-15T11:45:19.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286558957.md) - [en](https://longbridge.com/en/news/286558957.md) - [zh-HK](https://longbridge.com/zh-HK/news/286558957.md) --- # Immuneering | 8-K: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.21, beating the estimate of USD -0.252. EBIT: As of FY2026 Q1, the actual value is USD -16.7 M. ### Financial Overview #### Cash Position Immuneering Corporation concluded Q1 2026 with $198.6 million in cash, cash equivalents, and marketable securities, a decrease from $217.0 million as of December 31, 2025 . Specifically, cash and cash equivalents were $47,321,566 as of March 31, 2026, down from $128,645,025 at December 31, 2025 . Marketable securities (current) increased to $109,372,057 from $44,186,244, while non-current marketable securities slightly decreased to $41,950,745 from $44,183,186 over the same period . #### Research and Development (R&D) Expenses R&D expenses for Q1 2026 were $10,645,222, a decrease from $11,471,693 for Q1 2025 . This reduction was primarily due to decreased clinical spend related to the envometinib (IMM-6-415) program, partially offset by increased clinical costs for the atebimetinib program and other preclinical programs . #### General and Administrative (G&A) Expenses G&A expenses increased to $4,682,495 in Q1 2026 from $4,005,642 in Q1 2025, mainly driven by employee-related costs and higher professional fees . #### Total Operating Expenses Total operating expenses for Q1 2026 were $15,335,034, a slight decrease from $15,484,652 in Q1 2025 . #### Loss from Operations Loss from operations for Q1 2026 was -$15,335,034, compared to -$15,484,652 for Q1 2025 . #### Other Income (Expense) Interest income significantly increased to $1,360,404 in Q1 2026 from $438,520 in Q1 2025 . Other income, net, was $513,735 in Q1 2026, with no comparable amount reported in Q1 2025 . #### Net Loss Immuneering Corporation reported a net loss of -$13,460,895 for Q1 2026, an improvement from a net loss of -$15,046,132 for the same period in 2025 . #### Net Loss Per Share Net loss per share attributable to common stockholders was -$0.21 for Q1 2026, compared to -$0.42 for Q1 2025 . #### Comprehensive Loss Comprehensive Loss for Q1 2026 was -$13,783,232, which included an unrealized loss from marketable securities of -$322,337 . This compares to a comprehensive loss of -$15,046,132 for Q1 2025, which had no unrealized loss from marketable securities . #### Balance Sheet Highlights Total assets were $214,809,790 as of March 31, 2026, down from $231,985,010 as of December 31, 2025 . Total liabilities decreased to $8,291,619 from $13,501,042, while total stockholders’ equity was $206,518,171 compared to $218,483,968 over the same period . ### Operational Highlights and Unique Metrics New survival data from a Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer will be presented at the 2026 ASCO Annual Meeting . The pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line metastatic pancreatic cancer is now recruiting patients, with the first patient dosing on track for mid-2026 . A third-line pancreatic cancer patient receiving atebimetinib monotherapy has shown 27 months of progression-free survival to date, with an ongoing 85% reduction in tumor burden . ### Outlook / Guidance Immuneering Corporation anticipates its cash runway will be sufficient to fund operations into 2029, based on its cash, cash equivalents, and marketable securities as of March 31, 2026, and current operating plans . The company expects to report updated survival data at the 2026 ASCO annual meeting and dose the first patient in the pivotal Phase 3 MAPKeeper clinical trial by mid-2026 . Additionally, the first patient in the atebimetinib + Libtayo® trial for RAS-mutant first-line non-small cell lung cancer is expected to be dosed in the second half of 2026 . ### Related Stocks - [IMRX.US](https://longbridge.com/en/quote/IMRX.US.md) ## Related News & Research - [Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates | IMRX Stock News](https://longbridge.com/en/news/286557558.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Alpha Tau Q1 Net Loss Expands; Plans Enrollment Completion In IMPACT Study In Q3,2026; Stock Up](https://longbridge.com/en/news/286879279.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md)